According to current conception, the process of forming of nephrosclerosis despite the origins is detected by the force of the same cellular and molecular mechanisms. Hence primary triggers cause elevated production of range of cellular response mediators, cytokines and growth factors such as transforming plateled-derived growth factor, fibroblast growth factor, interferon gamma, nuclear factor and others, by means of sequential processes, is followed by the replacement of kidney tissue. One of the most studied aspects of the process of nephrosclerosis is the influence of anginotensin II. Therefore, despite the triggering factors, development and progression of nephrosclerosis all children with chronic renal disease are in a risk group with predisposition for renal insufficiency and it is required to prescribe nephroprotective therapy, i.e. the drugs that will influence one of the links of the nephrosclerosis, in order to slow down its progression. Currently, with nephroprotective goal in early age are used the following elements - angiotensin converting enzyme inhibitors and angiotensin receptors, antogonists (blockers). Lately, the active search for effective and safe drugs with nephroprotective effect on one side and great interest towards undiscovered before qualities of Vitamin D caused a huge amount of works that support the effect of Vitamin D. Prescription of Vitamin D to animals with uremia was followed by the drop of apoptosis of podocides and loss of the protein that is contained in the split diaphragm that caused decrease in proteinuria. Vitamin D suppresses protophibrotic TGF-B1 in tubular epithelial cells. The regression of tubulointerstitial phibrosis under the influence of Vitamin D was confirmed based on the cases of animals with obstruction of urethra. Along with the use of the mentioned above groups of drugs, which effectiveness was proved experimentally and clinically, we strongly believe the more thorough study of the Vitamin D drug use is needed, especially to study the prevention and slowing down of the progression of nephrosclerosis in the cases of children with chronic renal disease. It is crucial to detect the exact dosage of the drug, the prescription period and the methods for the control of the effective concentration of the drug.

Full Text

Restricted Access

About the authors

Sergey G. Semin

N.I. Pirogov Russian National Research Medical University (RNRMU)

117997, Moscow, Russian Federation
candidate of medical sciences, associate professor Pediatrican, N.I. Pirogov Russian National Research Medical University (RNRMU), 117997, Moscow, Russian Federation

O. B Kolbe

N.I. Pirogov Russian National Research Medical University (RNRMU)

117997, Moscow, Russian Federation

A. B Moiseev

N.I. Pirogov Russian National Research Medical University (RNRMU)

117997, Moscow, Russian Federation

A. I Turchinskaya

N.I. Pirogov Russian National Research Medical University (RNRMU)

117997, Moscow, Russian Federation

E. E Vartapetova

N.I. Pirogov Russian National Research Medical University (RNRMU)

117997, Moscow, Russian Federation


  1. Вялкова А.А. Хроническая болезнь почек в педиатрической нефрологии. Материалы Международной школы и научно-практической конференции по детской нефрологии «Актуальные проблемы детской нефрологии». Оренбург. 20i0; 63-75.
  2. Warady B.A., Chadha V. Chronic kidney disease in children: the global perspective. Pediatr. Nephrol. 2007; 22(i2): i999-2009.
  3. Kidney Disease: Improving Global 0utcomes (KDIG0) CKD Work Group. KDIG0 20i2 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 20i3; Suppl. 3: i-i50.
  4. Zaritsky J.J., Warady B.A. Chronic kidney disease in the neonate. Clin. Perinatol. 20i4; 4i(3): 503-i5.
  5. Антонов О.В., Китаева Ю.Ю., Комарова А.А. Концепция «Хронической болезни почек». Хроническая болезнь почек у детей: актуальность проблемы, определение понятия, классификация, современные подходы к формулировке диагноза. Медицина. 20i3; i: 24-28.
  6. Паунова С. С. Патогенетические основы нефросклероза. Нефрология и диализ. 2005; 2: i30-5.
  7. Смирнов И.Е., Кучеренко А.Г., Комарова О.В. Биомаркеры формирования нефросклероза при хронической болезни почек у детей. Российский педиатрический журнал. 20i4; i7(6): i0-4.
  8. Schlondorff D.O. Overview of factors contributing to the pathophysiology of progressive renal disease._Kidney. Int. 2008; 74(7): 860-6.
  9. Jefferson J.A., Shankland S.J. The pathogenesis of focal segmental glomerulosclerosis. Adv chron. Kidney. dis. 20i4; 2i(5): 408-i6.
  10. Yang H.C., Fogo A.B. Mechanisms of disease reversal in focal and segmental glomerulosclerosis. Adv. chron. Kidney. dis. 20i4; 2i(5): 442-7.
  11. Khan Z., Pandey M. Role of kidney biomarkers of chronic kidney disease: An update. saudi. J. Biol. Sci. 20i4; 2i(4): 294-9.
  12. Седашкина О.А., Куликова Н.И., Маковецкая Г.А., Печкуров Д.В. Молекулярно-генетические аспекты прогрессирования хронической болезни почек у детей (обзор литературы). Успехи современного естествознания. 20i5; 9-i: 8i-3.
  13. Зайкова Н.М., Длин В.В., Синицына Л.А., Корсунский А.А., Гацкан Ш.Г. Маркеры определения степени фиброгенеза у детей с пузырно-мочеточниковым рефлюксом. Педиатрия. 2015; 93( 3): 46-53.
  14. Вялкова А.А., Зорин И.В., Гордиенко Л.М., Мещерякова А.И., Егорочкина М.С., Савельева Е.В. Вопросы диагностики хронической болезни почек у детей. Практическая медицина. 2013; 6: 72-7.
  15. Морозов Д.А., Морозова О.Л., Захарова Н.Б., Лакомова Д.Ю., Чухрова Н.С., Стародубова А.В., Максимова А.В. Новые возможности ранней диагностики нефросклероза у детей с пузырно-мочеточниковым рефлюксом. Цитокины и воспаление. 2011; 10(2): 87-92.
  16. Lv L.L., Cao Y.H., Ni H.F., Xu M., Liu D., Liu H. et al. MicroRNA-29c in urinary exosome/microvesicle as a biomarker of renal fibrosis. Am. J. Physiol. Renal. Physiol. 2013; 305(8): 1220-7.
  17. Chaykovska L., Tsuprykov О., Hocher B. Biomarkers for the prediction of mortality and morbidity in patients with renal replacement therapy. Clin. Lab. 2011; 57(7-8): 455-67.
  18. Hussein A., Askar E, Elsaeid M., Schaefer F. Functional polymorphisms in transforming growth factor-beta-1 (TGFbeta-1) and vascular endothelial growth factor (VEGF) genes modify risk of renal parenchymal scarring following childhood urinary tract infection. Nephrol. Dial. Transplant. 2010; 25: 779-85.
  19. Lee RS. Biomarkers for peadiatric urological disease. Curr. Opin. Urol. 2009; 19 (4): 397-401.
  20. Liang X.L., Shi W., Hong Kong J. Beyond Early Diagnosis: Prognostic Biomarkers for Monitoring Acute Kidney Injury. Nephrol. 2010; 12 (2): 45-9.
  21. Margetts P.J., Hoff C., Liu L. Transforming growth factor в-induced peritoneal fibrosis is mouse strain dependent. Oxford Journals Medicine Nephrology Dialysis Transplantation. 2012; 28 (8): 201527.
  22. Смирнов И.Е., Кучеренко А.Г., Комарова О.В. Биомаркеры формирования нефросклероза при хронической болезни почек у детей. Российский педиатрический журнал. 2014; 17(6): 10-5.
  23. Комарова О.В., Кучеренко А.Г., Смирнов И.Е., Цыгин А.Н. Динамика содержания сывороточных маркеров апоптоза для оценки прогноза хронической болезни почек у детей. Вопросы современной педиатрии. 2013; 12(5): 104-7.
  24. Morales MG, Vazquez Y, Acuna MJ, et al. Angiotensin II-induced pro-fibrotic effects require p38MAPK activity and transforming growth factor beta 1 expression in skeletal muscle cells. Int. J. Biochem. Cell Biol. 2012; 44 (11): 1993-2002.
  25. Зорин И.В., Вялкова А.А., Ванюшина Л.В. Значение нарушений внутрипочечной гемодинамики в формировании и прогрессировании тубулоинтерстициального поражения почек у детей. Лечащий врач. 2016; 1: 37-43.
  26. Плешкова Е.М. Окислительный стресс и его участие в развитии и течении болезней мочевой системы у детей. Российский вестник перинатологии и педиатрии. 2014; 59(5): 9-14.
  27. Kohan D.E., Barton M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney. int. 2014. doi: 10.1038/ki.2014.143
  28. Kuruppu S., Rajapakse N.W., Smith A.I. Endothelin-converting enzyme-1 inhibition and renoprotection in end-stage renal disease. Pflugers. Arch. 2013; 465(7): 929-4.
  29. Malyszko J. Mechanism of endothelial dysfunction in chronic kidney disease. Clin. chim. Acta. 2010; 411(19-20): 1412-20.
  30. Shiraishi N., Tomita K. Progressive renal diseases: recent advances in diagnosis and treatments. Topics III. Recent topics 3. Nephrosclerosis. nihon naika Gakkai Zasshi. 2013; 102(5): 1180-9.
  31. Козыро И.А., Сукало А.В. Хроническая болезнь почек у детей. Педиатрия. Восточная Европа. 2013; 2: 112-9.
  32. Wuhl E., Mehls, F. Schaefer F. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int. 2004; 66: 768-76.
  33. Ellis D. et al. Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders. Am. J. Hypertens. 2004; 17:928-35.
  34. Wuhl E., Schaefer F. Therapeutic strategies to slow chronic kidney disease progression. Pediatr. Nephrol. 2008; 23: 705-16.
  35. Malluche HH1, Mawad H, Koszewski NJ.Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure. Kidney Int. 2002; 62(2): 367-74.
  36. Panichi V., De Pietro S., Andreini B., Bianchi A.M., Migliori M., Taccola D., Giovannini L., Tetta C., Palla R. Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium. Kidney Int. 1998 54:1463-1469.
  37. Xing N., Maldonadoa M.L., Bachmana L.A., McKeanb D.J., Kumara R., Griffin M.D. Distinctive dendritic cell modulation by vitamin D(3) and glucocorticoid pathways. Biochem. Biophys. Res. Commun. 2002; 297(3): 645-52.
  38. Panichi V., Migliori M., Taccola D., Filippi C., De Nisco L., Giovan-nini L., Palla R., Tetta C., Camussi G. Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int. 2001 Jul;60(1): 87-95.
  39. Agarwal R., Acharya M., Tian J., Hippensteel R.L., Melnick J.Z., Qiu P., Williams L., Batlle D. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005 Dec; 68(6): 2823-8.
  40. American Society of Nephrology Renal Research Report. J. Am. Soc. Nephrol. 2005 Jul; 16(7): 1886-903. Epub 2005 May 11.
  41. Subramaniam N., Leong G.M., Cock T.A. Cross-Talk between 1,25-dihydroxyvitamin D3 and transforming growth factor-beta signaling requires binding of VDR and Smad3 proteins to their cognate DNA recognition elements. J Biol Chem. 2001; 276: 15741-6.
  42. Yanagisawa J., Yanagi Y., Masuhiro Y., Suzawa M, Watanabe M., Kashiwagi K., Toriyabe T., Kawabata M., Miyazono K., Kato S. Convergence of transforming growth factor-0 and vitamin D signaling pathways on SMAD transcriptional coactivators. Science. 1999; 283: 1317-21.
  43. Tian J, Liu Y, Williams LA, de Zeeuw D. Potential role of active vitamin D in retarding the progression of chronic kidney disease. Nephrol Dial Transplant. 2007 Feb; 22(2): 321-8. Epub 2006 Nov 22.



Abstract - 30

PDF (Russian) - 0


Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies